Guardant Health Japan
Guardant Health Japan is the Japanese subsidiary of Guardant Health, a leading US-based precision oncology company. Since its establishment in 2012, Guardant Health has aimed to contribute to overcoming cancer through its proprietary cutting-edge technology for detecting genetic abnormalities from liquid biopsies, combined with advanced analytics leveraging AI and real-world data. The company utilizes liquid biopsy (liquid biopsy) to detect genetic abnormalities in cancer, employing advanced technology and extensive data analysis to contribute to cancer treatment. Their core product, Guardant360® CDx, is a comprehensive genomic profiling test for solid tumors, analyzing 74 gene variants, 18 gene amplifications, 6 gene fusions, and MSI-High status, and also serves as a companion diagnostic for various cancer therapies.
Guardant Health Japan
Guardant Health Japan is the Japanese subsidiary of Guardant Health, a leading US-based precision oncology company. Since its establishment in 2012, Guardant Health has aimed to contribute to overcoming cancer through its proprietary cutting-edge technology for detecting genetic abnormalities from liquid biopsies, combined with advanced analytics leveraging AI and real-world data. The company utilizes liquid biopsy (liquid biopsy) to detect genetic abnormalities in cancer, employing advanced technology and extensive data analysis to contribute to cancer treatment. Their core product, Guardant360® CDx, is a comprehensive genomic profiling test for solid tumors, analyzing 74 gene variants, 18 gene amplifications, 6 gene fusions, and MSI-High status, and also serves as a companion diagnostic for various cancer therapies.